& Co., Inc.Merck Sharp & Do... Net Worth

The estimated Net Worth of & Co., Inc.Merck Sharp & Do... is at least $23 Tisíc dollars as of 11 March 2024. Do owns over 21,397,205 units of Harpoon Therapeutics stock worth over $23,010 and over the last few years sold HARP stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Do HARP stock SEC Form 4 insiders trading

has made over 1 trades of the Harpoon Therapeutics stock since 2024, according to the Form 4 filled with the SEC. Most recently bought 21,397,205 units of HARP stock worth $492,135,715 on 11 March 2024.

The largest trade 's ever made was buying 21,397,205 units of Harpoon Therapeutics stock on 11 March 2024 worth over $492,135,715. On average, trades about 21,397,205 units every 0 days since 2024. As of 11 March 2024 still owns at least 1,000 units of Harpoon Therapeutics stock.

You can see the complete history of Do stock trades at the bottom of the page.

What's Do's mailing address?

's mailing address filed with the SEC is 126 EAST LINCOLN AVENUE126 EAST LINCOLN AVENUE, , RAHWAYRAHWAY, NJNJ, 0706507065.

Insiders trading at Harpoon Therapeutics

Over the last 6 years, insiders at Harpoon Therapeutics have traded over $62,512,704 worth of Harpoon Therapeutics stock and bought 26,100,850 units worth $525,945,967 . The most active insiders traders include & Co., Inc.Merck Sharp & Do..., Ronald Hunt a Bioscience Plc Arix Bioscie.... On average, Harpoon Therapeutics executives and independent directors trade stock every 26 days with the average trade being worth of $9,736,866. The most recent stock trade was executed by & Co., Inc.Merck Sharp & Do... on 11 March 2024, trading 21,397,205 units of HARP stock currently worth $492,135,715.

What does Harpoon Therapeutics do?

Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company's lead tri-specific t-cell activating construct (TriTAC) product candidate is HPN424, which is in Phase I/IIa clinical trials for the treatment of metastatic castration-resistant prostate cancer. It is also developing HPN536, which is in Phase I/IIa clinical trials for the treatment of ovarian cancer and other mesothelin-expressing tumors; HPN217 that is in Phase I/II clinical trials for the treatment of multiple myeloma; and HPN328, a product candidate in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors. The company has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate our proprietary TriTAC platform technology together with soluble T cell receptors. Harpoon Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California.

Complete history of Do stock trades at Harpoon Therapeutics

Harpoon Therapeutics executives and stock owners

Harpoon Therapeutics executives and other stock owners filed with the SEC include:

• Gerald McMahon,
  President, Chief Executive Officer, Director
• Dr. Natalie R. Sacks M.D.,
  Chief Medical Offer
• Holger Wesche,
  Chief Scientific Officer
• Georgia L. Erbez,
  Chief Financial Officer
• Georgia Erbez,
  Chief Financial Officer
• Natalie Sacks,
  Chief Medical Officer
• Mark Chin,
  Independent Director
• Julia Eastland,
  Independent Director
• Ronald Hunt,
  Chairman of the Board
• Scott Myers,
  Independent Director
• Jonathan Drachman,
  Independent Director
• Joanne Viney,
  Independent Director
• Andrew Robbins,
  Independent Director
• Joseph Bailes,
  Independent Director
• Karin Thacker,
  Vice President - Regulatory Affairs and Quality Assurance
• Omer Siddiqui,
  Vice President - Development Operations and Project Management
• Rachael Lester,
  Vice President of Corporate Development
• Che-Leung Law,
  Vice President - Translational Medicine
• Christopher Whitmore,
  Vice President - Finance
• Susan Jones,
  Senior Vice President, Product Development
• Dr. Holger Wesche Ph.D.,
  Chief Scientific Officer
• Julie M. Eastland,
  Pres, CEO & Director
• James B Bucher,
  Chief Legal Officer
• Alan Colowick,
  Director
• Bio Ventures 2014, L.P.Mpm ...,
  
• Ansbert Oncology Impact Fun...,
  
• Bio Ventures 2014, L.P.Mpm ...,
  
• Patrick Baeuerle,
  Director
• Bioscience Plc Arix Bioscie...,
  
• Luke Evnin,
  Director
• Oncology Impact Fund L.P.On...,
  
• Leaf Ventures Iii, L.P.New ...,
  
• Leaf Biopharma Opportunitie...,
  
• Lauren P Silvernail,
  
• Frank J Lanza,
  Principal Fin. & Acctng Ofc.
• Luke Nathaniel Walker,
  Chief Medical Officer
• & Co., Inc.Merck Sharp & Do...,